Cytokinetics, Incorporated Forecast, price target & analysts
Cytokinetics, Incorporated Target price 2026 - Analyst rating & recommendation
Cytokinetics, Incorporated Classifications & Recommendation:
Cytokinetics, Incorporated Price Target
| Target Price | $81.60 |
| Price | $61.73 |
| Potential |
32.19%
register free of charge
|
| Number of Estimates | 20 |
|
20 Analysts have issued a price target Cytokinetics, Incorporated 2027 .
The average Cytokinetics, Incorporated target price is $81.60.
This is
32.19%
register free of charge
$126.00
104.11%
register free of charge
$61.61
0.19%
register free of charge
|
|
| A rating was issued by 26 analysts: 21 Analysts recommend Cytokinetics, Incorporated to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Cytokinetics, Incorporated stock has an average upside potential 2027 of
32.19%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 18.47 | 82.47 |
| 145.29% | 346.52% | |
| EBITDA Margin | -2,851.76% | -748.42% |
| 55.66% | 73.76% | |
| Net Margin | -3,191.82% | -963.89% |
| 54.33% | 69.80% |
22 Analysts have issued a sales forecast Cytokinetics, Incorporated 2025 . The average Cytokinetics, Incorporated sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an Cytokinetics, Incorporated EBITDA forecast 2025. The average Cytokinetics, Incorporated EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
22 Cytokinetics, Incorporated Analysts have issued a net profit forecast 2025. The average Cytokinetics, Incorporated net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -5.26 | -6.51 |
| 3.49% | 23.76% | |
| P/E | negative | |
| EV/Sales | 92.76 |
22 Analysts have issued a Cytokinetics, Incorporated forecast for earnings per share. The average Cytokinetics, Incorporated EPS is
This results in the following potential growth metrics and future valuations:
Cytokinetics, Incorporated...
Current Cytokinetics, Incorporated Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Dec 23 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Dec 22 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 22 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Dec 22 2025 |
| Citizens |
Locked
➜
Locked
|
Locked | Dec 22 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Dec 22 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Dec 19 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Dec 23 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Dec 22 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 22 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Dec 22 2025 |
|
Locked
Citizens:
Locked
➜
Locked
|
Dec 22 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Dec 22 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Dec 19 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
